Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Inc.

www.amgen.com

Latest From Amgen Inc.

He's Handled More ANDA Cases Than Anyone, And Now He's Retiring: Judge Sleet Reflects On His Career

In an interview with the Pink Sheet, Delaware District Judge Sleet discusses patent reform fallout and major issues facing district courts.

Legal Issues Intellectual Property

Rigel Readies Tavalisse For Late-May Launch After FDA Approval

Rigel has its first US FDA approval for Tavalisse (fostamatinib) and plans to launch the drug for adults with immune thrombocytopenia (ITP) in late May, after working on the drug's development for more than a decade across multiple indications.

Approvals Immune Disorders

Pipeline Watch: Phase III Top-Line Results With Upadacitinib, Keytruda And Cosentyx

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 


Pipeline Watch Approvals

New Migraine Drugs May Not Be Cost Effective In Patients With Other Options, ICER Suggests

Draft cost effectiveness report released by the Institute for Clinical and Economic Review uses $8,500 annual cost for Aimovig and fremanezumab as a "placeholder" price.

United States Cost Effectiveness
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register